Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2022
  • CME

June 3-7, 2022; Chicago, Illinois
Expert faculty review and share their insights and perspectives on key studies in the management of lung cancer presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Stephen V. Liu, MD
Zofia Piotrowska, MD, MHS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: September 1, 2022 Expiration: August 31, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with lung cancer
  • Identify subpopulations of patients with lung cancer most likely to benefit from a specific treatment plan based on predictive biomarkers
  • Evaluate new data on novel agents and therapeutic approaches for patients with lung cancer


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Stephen V. Liu, MD

Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech, Gilead, Guardant Health, Janssen, Jazz, Lilly, Merck, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher: Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Gilead, Lilly, Merck, Merus, Nuvalent, Pfizer, Rain Therapeutics, RAPT, Turning Point Therapeutics.
Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AstraZeneca, Blueprint, C4 Therapeutics, Cullinan, Daiichi Sankyo, Janssen, Jazz, Lilly, Takeda; researcher: AbbVie, AstraZeneca, Blueprint, Cullinan, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro/GlaxoSmithKline.


Anna Poppa

Editorial Contributor

Anna Poppa has no relevant financial relationships to disclose.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.
Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
Brian Purves, PharmD, MBA
Brian Purves has no relevant financial relationships to disclose.
Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with lung cancer


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with lung cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 01, 2022, through August 31, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expertengespräch über die Daten der Jahresversammlung der SOHO 2022 zu BTK-Inhibitoren bei CLL und MCL, von Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Comentario experto de los datos de la Junta Anual de SOHO 2022 sobre inhibidores de la TQB para LLC y LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Comentários de especialistas sobre dados da Reunião Anual da SOHO 2022 sobre os inibidores de BTK para LLC e LCM, do Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Commenti di esperti sui dati della Conferenza annuale della SOHO 2022 sugli inibitori di BTK per il trattamento di CLL e MCL, a cura di Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings